JAYKAYJaykay Enterprises Ltd.

    Jaykay Enterprises Q2 FY27 Results: Standalone Net Profit ₹0.49 Crore on Total Income of ₹9.96 Crore

    • Earnings
    • defence and digital manufacturing

    Jaykay Enterprises (NSE: JAYKAY) reported standalone total income of ₹9.96 crore and net profit of ₹0.49 crore for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026. The filing covers the standalone results only; the consolidated statement is not among the pages read.

    Key highlights

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹9.96 crore, up 218.5% YoY and 246.5% QoQ
    • Net profit and EPS: ₹0.49 crore, down 50.9% YoY; basic EPS ₹0.04 against ₹0.08 a year earlier
    • Finance costs: ₹0.26 crore, up 637.2% YoY
    • Other income: ₹1.26 crore, down 47.5% YoY and flat QoQ

    Summary

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    9.963.13+218.5%2.88+246.5%
    0.491.01-50.9%0.01n/a
    EPS, basic (₹)0.040.08-50.0%0.00n/a

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Income grew far faster than profit this quarter. Other income of ₹1.26 crore is 12.7% of total income and 211.6% of profit before tax of ₹0.60 crore, so the pre-tax profit is smaller than the other income it contains.

    Finance costs rose sharply, from ₹0.04 crore to ₹0.26 crore, which is 2.6% of total income.

    The statutory auditors gave an unmodified conclusion on the standalone results, with an emphasis of matter on the subsidiary Neumesh Labs Private Limited. The auditors put the company's total exposure to Neumesh at ₹22.32 crore as of 30 Sep 2026, including interest receivable of ₹3.60 crore. The subsidiary's net worth is negative ₹35.34 crore and its current liabilities exceed current assets by ₹36.31 crore. The filing says Neumesh has temporarily paused commercial operations and is formulating a business plan in digital services. Management considers the carrying value recoverable and has recognised no provision for impairment in the quarter or half year.

    Inference

    The filing reports a 2,05,71,642 rights equity share issue on 23 Sep 2026 at a premium of ₹74 per share, with ₹0.50 per share paid up, and a standalone paid-up equity share capital of ₹14.06 crore at 30 Sep 2026. It also records two rights issue utilisation notes: one for ₹146.14 crore under a letter of offer dated 17 Aug 2024 with an amount unutilised at 30 Sep 2026, and one for ₹77.14 crore under a letter of offer dated 25 Aug 2026 with no funds utilised against the listed objects at that date. On 21 Oct 2026 the Nomination and Remuneration Committee approved 13,000 employee stock options under the JKE Employee Stock Option Scheme 2025.

    The filing does not say what the exceptional items of ₹260.36 crore in the year ended 31 Mar 2026 relate to, why other income fell, or how and when Neumesh Labs will be revived; these are not known from the filing.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Jaykay Enterprises Ltd. articles